Fact Source: Financial Supervisory Service DART / 2026-03-13
Disclosure Type: Execution of Single Sales/Supply Contract
💡 3-Second Summary
Samsung Biologics has announced a pharmaceutical Contract Manufacturing Organization (CMO) agreement worth approximately KRW 279.6B (USD 188.95M) with a European pharmaceutical company. Initially signed in August 2025 below the regulatory disclosure threshold, the contract has now been officially disclosed as the minimum purchase quantity was finalized following the fulfillment of contract terms.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Contract Category & Title: Other Sales/Supply Contract / Contract Manufacturing Agreement for Pharmaceuticals
- Contract Amount: KRW 279,608,210,000 (Converted from the fixed contract value of USD 188,950,000 using the initial base exchange rate of KRW 1,479.80/USD as of March 13, 2026)
- Ratio to Revenue: 6.15% (Compared to the recent revenue of KRW 4.55T from the 2024 consolidated financial statements)
- Counterparty: A pharmaceutical company located in Europe (Identity and specific supply region are temporarily withheld due to operational confidentiality requirements; confidentiality expiration date is set to 2032-03-13)
- Contract Period: Start Date: 2025-07-31 ~ End Date: 2032-03-13 (Approximately 6 years and 7 months)
- Contract (Order) Date: 2025-08-11
- Other Details: No down payment or advance payment is involved. Payment terms are not specified. The contract expiration date and the information disclosure withholding period may change subject to mutual agreement. The disclosure does not state specific reasons for the change in earnings performance.
📈 2. [Expert View: What This Disclosure Means for Investors]
This filing serves as a fundamental development confirming that Samsung Biologics has secured a mid-to-long-term order within its CMO business. Representing 6.15% of its recent annual revenue and structured as a long-term supply agreement extending over 6 years, this transaction carries a potential impact that may support steady revenue flows.
A key fact is that while this order was initially received in August 2025, it was not disclosed at that time because it fell short of regulatory disclosure thresholds. The official filing was triggered on March 13, 2026, as the fulfillment of contractual terms finalized the minimum purchase quantity, causing the transaction to meet the disclosure threshold. The non-disclosure of the counterparty’s identity until 2032 due to business confidentiality presents an information restriction for public evaluation, but adding an order record in Europe remains verified. Since this contract is denominated in USD, minor adjustments in KRW-converted figures may occur depending on future foreign exchange rate movements. Investors should evaluate this disclosure based on the confirmed order backlog figures rather than introducing speculative interpretations regarding contract clauses.
📝 Editor’s Comment (by K-STOCK Editor)
Samsung Biologics’ latest supply contract disclosure underscores the company’s order backlog trend within the global CMO industry. The transition of this relationship, which began in August 2025, into a public disclosure due to the finalization of minimum purchase volumes highlights that the transaction value has met regulatory criteria. Although operational confidentiality clauses will keep the specific client’s identity veiled until 2032, this milestone confirms an ongoing mid-to-long-term partnership with a European pharmaceutical company. Spanning over six years and accounting for more than 6% of recent revenue, this contract provides a potential fundamental catalyst that may support stable baseline revenue. Global investors should focus on the confirmed contract values while considering potential adjustments from foreign exchange rates.
📢 Disclaimer & Source Information
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
